0002-3115

Generic: galcanezumab-gnlm

Labeler: eli lilly and company
NDC Directory DRUG FOR FURTHER PROCESSING DRUG FOR FURTHER PROCESSING Active

Drug Facts

Product Profile

Brand Name
Generic Name galcanezumab-gnlm
Labeler eli lilly and company
Dosage Form INJECTION, SOLUTION
Active Ingredients

galcanezumab 100 mg/mL

Identifiers & Regulatory

Product NDC 0002-3115
Product ID 0002-3115_368df5d9-5eeb-49c7-a0dd-8a326ee5d78f
Product Type DRUG FOR FURTHER PROCESSING
Marketing Category DRUG FOR FURTHER PROCESSING
Listing Expiration 2026-12-31
Marketing Start 2019-06-04

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00023115
Hyphenated Format 0002-3115

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name emgality (source: label)
Generic Name galcanezumab-gnlm (source: ndc)
Application Number BLA761063 (source: label)
Routes
subcutaneous
source: label

Resolved Composition

Strengths
  • 100 mg/mL
source: ndc
Packaging
  • 1 mL in 1 SYRINGE (0002-3115-00)
source: ndc

Packages (1)

Ingredients (1)

galcanezumab (100 mg/mL)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"spl_id": "368df5d9-5eeb-49c7-a0dd-8a326ee5d78f", "openfda": {}, "finished": false, "packaging": [{"description": "1 mL in 1 SYRINGE (0002-3115-00)", "package_ndc": "0002-3115-00", "marketing_start_date": "04-JUN-19"}], "product_id": "0002-3115_368df5d9-5eeb-49c7-a0dd-8a326ee5d78f", "dosage_form": "INJECTION, SOLUTION", "product_ndc": "0002-3115", "generic_name": "galcanezumab-gnlm", "labeler_name": "Eli Lilly and Company", "product_type": "DRUG FOR FURTHER PROCESSING", "brand_name_base": null, "active_ingredients": [{"name": "GALCANEZUMAB", "strength": "100 mg/mL"}], "marketing_category": "DRUG FOR FURTHER PROCESSING", "marketing_start_date": "20190604", "listing_expiration_date": "20261231"}